• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

    9.370 +0.070 (+0.75%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Intellia Therapeutics, Inc. - Common Stock

    < Previous 1 2
    ...
    14 15 16 17 18 19 20 21 Next >
    News headline image
    Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test ↗
    Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
    Via Investor's Business Daily
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Gainers GBS (NASDAQ:GBS) stock rose 10.9% ... 
    Via Benzinga
    News headline image
    The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
    Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the... 
    Via Talk Markets
    News headline image
    The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
    Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
    Via Benzinga
    News headline image
    Analyst Ratings For Intellia Therapeutics ↗
    Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter: 
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022 ↗
    Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago... 
    Via Benzinga
    News headline image
    How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months? ↗
    Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains. The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020,... 
    Via Benzinga
    News headline image
    Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them? ↗
    Can the formerly red-hot biotech segment return to its previous glory? 
    Via Investor's Business Daily
    News headline image
    Intellia Therapeutics Pops After Forging A Cancer Deal Worth Nearly $1 Billion ↗
    Intellia will receive up to $920 million in payments for five potential treatments. 
    Via Investor's Business Daily
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗
    Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For February 7, 2022 ↗
    Upgrades For Enova International Inc (NYSE:ENVA), Maxim Group upgraded the previous rating of Hold to Buy. For the fourth quarter, Enova International had an EPS of $1.61,... 
    Via Benzinga
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗
    Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
    Via Benzinga
    News headline image
    Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗
    A rebound from Monday's lows faded, with the key indexes all down for the week. 
    Via Investor's Business Daily
    News headline image
    If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today ↗
    Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 32.37% on an annualized basis. Buying $1,000 In NTLA: 5 years ago, an investor could have... 
    Via Benzinga
    News headline image
    The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗
    Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
    Via Investor's Business Daily
    News headline image
    Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗
    The companies hope to cure diseases of the liver, muscle and central nervous system. 
    Via Investor's Business Daily
    News headline image
    What 4 Analyst Ratings Have To Say About Intellia Therapeutics ↗
    Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:... 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Gainers SomaLogic (NASDAQ:SLGC) shares mo... 
    Via Benzinga
    News headline image
    Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗
    2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
    Via InvestorPlace
    News headline image
    36 Stocks Moving In Tuesday's Mid-Day Session ↗
    Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.... 
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗
    Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
    Via Benzinga
    News headline image
    54 Biggest Movers From Yesterday ↗
    Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and... 
    Via Benzinga
    News headline image
    Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗
    CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations. 
    Via The Motley Fool
    News headline image
    Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗
    Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
    Via Benzinga
    News headline image
    Looking for Growth in Small and Mid Cap Life Science Stocks ↗
    2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
    Via Talk Markets
    News headline image
    Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript ↗
    NTLA earnings call for the period ending October 3, 2021. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
    Via Benzinga
    News headline image
    The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
    Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
    Via Benzinga
    News headline image
    EVP And Chief Medical Officer Of Intellia Therapeutics Trades $340K In Company Stock ↗
    David Lebwohl, EVP And Chief Medical Officer at Intellia Therapeutics (NASDAQ:NTLA), made a large buy and sell of company shares on October 14, according to a new SEC filing. What... 
    Via Benzinga
    Topics Regulatory Compliance
    < Previous 1 2
    ...
    14 15 16 17 18 19 20 21 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.